CEO Interviews

Contravir (NASDAQ: CTRV) Interview with CEO James Sapirstein in which he discusses recent funding and CRV431 progress

Contravir Pharmaceuticals (NASDAQ: CTRV) CEO: James Sapirstein   INTERVIEW TRANSCRIPTS: WSA:  Good day from Wall Street, this is Juan Costello Senior Analyst with the Wall Street Analyzer. Joining us today is James Sapirstein CEO for […]